New York Cancer and Blood Specialists

Clinical research site in Shirley, New York

Part of New York Cancer and Blood Specialists

As of July 2026, 10 paid clinical trials are recruiting at New York Cancer and Blood Specialists in Shirley, New York. Active studies at this site cover conditions such as Colorectal Neoplasms, Breast Neoplasms and Carcinoma, Non-Small-Cell Lung. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at New York Cancer and Blood Specialists (10)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

28 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

48 locations incl. Tucson

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

129 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

11 locations incl. Springdale

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07518186·Phase 3·Recruiting·Listed Apr 2026

Apply to this trial

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

for Nausea

20 locations incl. Greenbrae

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07169851·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

for Cachexia

12 locations incl. Beverly Hills

Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05865535·Phase 1·Recruiting·Listed May 2023

Apply to this trial

More research sites in Shirley

North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists (2 trials)
Ny Cancer and Blood Specialists (2 trials)
Local Institution - 0079 (1 trial)
NYCBS (1 trial)
New York Cancer & Blood Specialists (1 trial)
New York Cancer & Blood Specialists (NYCBS) (1 trial)
New York Cancer And Blood Specialists - Shirley (1 trial)
New York Cancer and Blood Specialists One Oncology (1 trial)
Suffolk Surgery Center (1 trial)
Vitreoretinal Consultants (1 trial)

Explore more

Paid clinical trials in Shirley, NY · New York clinical trials